Highest Analyst Upside Stocks
HROW is part of our highest analyst upside stock list, indicating analysts have a price target way above the current price.
NASDAQ:HROW • US4158581094
The current stock price of HROW is 38.75 USD. Today HROW is down by -1%. In the past month the price increased by 6.6%. In the past year, price increased by 51.66%.
HROW currently appears in the following ChartMill screener lists.
ChartMill assigns a technical rating of 4 / 10 to HROW. When comparing the yearly performance of all stocks, HROW is one of the better performing stocks in the market, outperforming 75.34% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to HROW. Both the profitability and the financial health of HROW get a neutral evaluation. Nothing too spectacular is happening here.
On March 2, 2026 HROW reported an EPS of 0.17 and a revenue of 89.09M. The company missed EPS expectations (-54.8% surprise) and missed revenue expectations (-1.25% surprise).
14 analysts have analysed HROW and the average price target is 68.05 USD. This implies a price increase of 75.61% is expected in the next year compared to the current price of 38.75.
For the next year, analysts expect an EPS growth of 2289.71% and a revenue growth 29.34% for HROW
Over the last trailing twelve months HROW reported a non-GAAP Earnings per Share(EPS) of 0.02. The EPS increased by 104.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.29% | ||
| ROE | -9.8% | ||
| Debt/Equity | 4.64 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.24 | 870.633B | ||
| JNJ | JOHNSON & JOHNSON | 18.18 | 544.587B | ||
| MRK | MERCK & CO. INC. | 22.51 | 278.825B | ||
| PFE | PFIZER INC | 8.92 | 152.448B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.32 | 120.054B | ||
| ZTS | ZOETIS INC | 16.41 | 49.42B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.61 | 28.686B | ||
| VTRS | VIATRIS INC | 5.91 | 16.907B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.28 | 11.216B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.535B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.281B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.098B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.08 | 4.954B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
The company is headquartered in Nashville, Tennessee and currently employs 373 full-time employees. The company went IPO on 2013-02-08.
IPO: 2013-02-08
HARROW INC
1A Burton Hills Blvd, Suite 200
Nashville TENNESSEE 37205 US
CEO: Mark L. Baum
Employees: 373
Phone: 18004831140
The company is headquartered in Nashville, Tennessee and currently employs 373 full-time employees. The company went IPO on 2013-02-08.
The current stock price of HROW is 38.75 USD. The price decreased by -1% in the last trading session.
HROW does not pay a dividend.
HROW has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
HROW stock is listed on the Nasdaq exchange.
The PE ratio for HARROW INC (HROW) is 1937.5. This is based on the reported non-GAAP earnings per share of 0.02 and the current share price of 38.75 USD.
You can find the ownership structure of HARROW INC (HROW) on the Ownership tab.